These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8675729)

  • 1. VS38 immunostaining in melanocytic lesions.
    Shanks JH; Banerjee SS
    J Clin Pathol; 1996 Mar; 49(3):205-7. PubMed ID: 8675729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution of monoclonal antibody HMB45 in the histopathologic diagnosis of melanoma].
    Pluot M; Joundi A; Grosshans E
    Ann Dermatol Venereol; 1990; 117(10):691-9. PubMed ID: 1705764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VS38 immunostaining in neuroendocrine tumours.
    Banerjee SS; Shanks JH; Hasleton PS
    Histopathology; 1997 Mar; 30(3):256-9. PubMed ID: 9088955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Clinicopathological Features in Spontaneous Regression of Melanomas and Melanocytic Naevi.
    Martín JM; Pinazo I; Jordá E; Monteagudo C
    Acta Derm Venereol; 2017 Jun; 97(6):692-697. PubMed ID: 28224168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
    Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
    Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
    Lampert A; Thomine E; Lauret P; Hemet J
    Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
    Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
    Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker.
    Maeda A; Aragane Y; Tezuka T
    Br J Dermatol; 1998 Aug; 139(2):198-206. PubMed ID: 9767232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of VS38 in osteoblasts and stroma cells of bone tumors.
    Sulzbacher I; Fuchs M; Chott A; Lang S
    Pathol Res Pract; 1997; 193(9):613-6. PubMed ID: 9521019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
    Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
    Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of nm23 protein expression in malignant melanoma. An immunohistochemical study.
    van den Oord JJ; Maes A; Stas M; Nuyts J; De Wever I; De Wolf-Peeters C
    Melanoma Res; 1997 Apr; 7(2):121-8. PubMed ID: 9167178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion molecule profile and malignancy of melanocytic lesions.
    Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
    Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fascin expression in melanocytic lesions of the skin.
    YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
    Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nevus associated malignant melanomas--diagnostic validation and prognosis].
    Stadler R; Garbe C
    Hautarzt; 1991 Jul; 42(7):424-9. PubMed ID: 1938395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties.
    Kanter L; Blegen H; Wejde J; Lagerlöf B; Larsson O
    Melanoma Res; 1995 Oct; 5(5):345-50. PubMed ID: 8541725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical investigation of alpha1 (IV) and alpha5 (IV) collagen chains in a broad spectrum of melanocytic tumours.
    Quatresooz P; Piérard GE
    Melanoma Res; 2005 Jun; 15(3):161-8. PubMed ID: 15917697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.